Retroviral vectors that are both non-replicating and non-integrating represent a novel and attractive tool that has potential advantages for gene delivery therapy, immunotherapy, and vaccinology ...

Retroviral vectors that are both non-replicating and non-integrating represent a novel and attractive tool that has potential advantages for gene delivery therapy, immunotherapy, and vaccinology. SAN ...

Retroviral vectors that are both non-replicating and non-integrating represent a novel and attractive tool that has potential advantages for gene delivery therapy, immunotherapy, and vaccinology. SAN ...

Retroviral vectors that are both non-replicating and non-integrating represent a novel and attractive tool that has potential advantages for gene delivery therapy, immunotherapy, and vaccinology.

In a phase 3 trial, 81% of wounds treated with autologous cell sheet-based gene therapy showed ≥ 50% healing at 6 months, compared with 16% in matched control wounds treated with standard of care.

This article examines viral and non-viral vectors in gene therapy, highlighting their mechanisms, advantages, and limitations ...

The recombinant vector contains only both LTRs, the packaging signal and the therapeutic transgene (s) and/or a reporter gene replacing the original sequences coding for viral proteins.